The low or decrease in Bcl-2 expression is associated with treatment response in human breast cancer studies (26, 27), similar to the lack or low Bax expression from 5-FU-based adjuvant therapies in human colorectal carcinoma (52). The gene discussed is BCL2; the disease is colorectal carcinoma.